Clinical Trials · NCT02311673

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Name: Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Setmelanotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 40
Start date: Mar 2015
Locations: 5 sites, United States
Primary endpoint: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2

View Setmelanotide compound reference